Evidence map›Paper›PMID 28724651›Full record

ArticleJournal of the American Heart Association2017

Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.

Ghassan Bandak, Yingying Sang, Alessandro Gasparini, Alex R Chang, Shoshana H Ballew, Marie Evans, Johan Arnlov, Lars H Lund, Lesley A Inker, Josef Coresh and 2 more

2 registry-linked trialsOpen access · goldAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 91 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 5 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04141800 completednot on this mapstarted 2019, after this paper: background citation

Spanish Multicentric Study of Hyperkalaemia Prevalence, Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fraction

Typeobservational_patient_registrySponsorSpanish Society of CardiologyRan2019 to 2021Enrolled565ConditionsHeart Failure With Reduced Ejection Fraction, Hyperkalemia
NCT05155436 phase4completednot on this mapstarted 2022, after this paper: background citation

Prevalence and Incidence of Dyskalemia in Hypertensive Patients Initiating a Fixed Dose Combination Pill of Telmisartan and Amlodipine

TypeinterventionalSponsorNational Heart Foundation of BangladeshRan2022 to 2023Enrolled1,090ConditionsHypertension, Potassium ImbalanceArmsFixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 5 syntheses or guidelines pooled it, 172 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Ghassan BandakDivision of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD.
Yingying SangDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.
Alessandro GaspariniDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Alex R ChangDivision of Nephrology, Geisinger Health System, Danville, PA.
Shoshana H BallewDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.
Marie EvansDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Johan ArnlovDepartment of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala, Sweden.
Lars H LundUnit of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Lesley A InkerDivision of Nephrology, Tufts Medical Center, Boston, MA.
Josef CoreshDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.
Juan-Jesus CarreroDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Morgan E GramsDivision of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD mgrams2@jhmi.edu.
Johns Hopkins University · USKarolinska Institutet · SEGeisinger Health System · USTufts Medical Center · USUppsala University · SE

Funding

Morbid Obesity, Bariatric Surgery, and Kidney FunctionK23DK106515 · NIDDK · GEISINGER CLINIC · PI CHANG, ALEXANDER R · 2015 to 2019
$890k
NIDDK NIH HHS K23 DK106515
6 · The paper itself

Abstract

backgroundConcerns about hyperkalemia limit the use of angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs), but guidelines conflict regarding potassium-monitoring protocols. We quantified hyperkalemia monitoring and risks after ACE-I/ARB initiation and developed and validated a hyperkalemia susceptibility score. METHODS AND

resultsWe evaluated 69 426 new users of ACE-I/ARB therapy in the Stockholm Creatinine Measurements (SCREAM) project with medication initiation from January 1, 2007 to December 31, 2010, and follow-up for 1 year thereafter. Three fourths (76%) of SCREAM patients had potassium checked within the first year. Potassium >5 and >5.5 mmol/L occurred in 5.6% and 1.7%, respectively. As a comparison, we propensity-matched new ACE-I/ARB users to 20 186 new β-blocker users in SCREAM: 64% had potassium checked. The occurrence of elevated potassium levels was similar between new β-blocker and ACE-I/ARB users without kidney disease; only at estimated glomerular filtration rate <60 mL/min per 1.73 m

conclusionsHyperkalemia within the first year of ACE-I/ARB therapy was relatively uncommon among people with estimated glomerular filtration rate >60 mL/min per 1.73 m

Indexed as

AdultAgedAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBiomarkersCreatinineDatabases, FactualDrug MonitoringFemaleGlomerular Filtration RateHumansHyperkalemiaKidneyLogistic ModelsMaleMiddle AgedAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBiomarkersCreatininePotassiumangiotensin‐converting enzyme inhibitionangiotensin‐converting enzyme inhibitorsangiotensin receptor blockerschronic kidney diseasehyperkalemiapotassiumrisk score

Identifiers

PMID28724651
PMCPMC5586281
OpenAlexW2737005781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.